ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.340,57
0,65%
S&P 500
5.936,48
-0,65%
Dow Jones
42.678,60
-0,07%
Euro vs US Dollar
1,03551
-0,27%
Bitcoin
96.881,33
-5,28%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Poseida Therapeutics Inc (PSTX) Börsenkurse

Poseida Therapeutics Inc

Poseida Therapeutics Inc (PSTX)

NASDAQ
9,60
0,04
( 0,42% )
Aktualisiert: 19:52:48
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
9,60
Gebot
9,60
Fragen
9,61
Volumen
1.705.571
9,575 Tagesbereich 9,67
1,87 52-Wochen-Bereich 9,67
Marktkapitalisierung
935,664M
Handelsende
9,56
Handelsbeginn
9,578
Letzte Trade
7
@
9.6
Letzter Handelszeitpunkt
19:52:48
Finanzvolumen
US$ 16.401.149
VWAP
9,6162
Durchschnittliches Volumen (3 Mio.)
1.422.290
Ausgegebene Aktien
97.465.024
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-7,59
Gewinn pro Aktie (EPS)
-1,27
Erlöse
64,7M
Nettogewinn
-123,43M

Über Poseida Therapeutics Inc

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T... Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.poseida.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Poseida Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PSTX. The last closing price for Poseida Therapeutics was US$9,56. Over the last year, Poseida Therapeutics shares have traded in a share price range of US$ 1,87 to US$ 9,67.

Poseida Therapeutics currently has 97.465.024 shares in issue. The market capitalisation of Poseida Therapeutics is US$931,77 million. Poseida Therapeutics has a price to earnings ratio (PE ratio) of -7.59.

PSTX Neueste Nachrichten

Weitere Nachrichten

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

6 Stunden vor
Edgar (US Regulatory)

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

21 Stunden vor
Edgar (US Regulatory)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

27 Dezember 2024
Edgar (US Regulatory)

Form SC 14D9 - Solicitation, recommendation statements

09 Dezember 2024
Edgar (US Regulatory)

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual...

09 Dezember 2024
PR Newswire (US)

Form SC14D9C - Written communication relating to third party tender offer

27 November 2024
Edgar (US Regulatory)

Form SC14D9C - Written communication relating to third party tender offer

26 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

26 November 2024
Edgar (US Regulatory)

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. PR Newswire SAN DIEGO, Nov. 26, 2024 Poseida stockholders to receive up to $13.00 per share in cash...

26 November 2024
PR Newswire (US)

Form 8-K - Current report

14 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.11.052631578959.59.679.3923469379.50861731CS
40.181.910828025489.429.679.3612212269.48547793CS
127.11285.5421686752.499.672.3214222908.14658821CS
266.57216.8316831683.039.672.328902776.75211196CS
526.47206.7092651763.139.671.877592135.28748666CS
1563.0646.78899082576.549.671.547198064.15012031CS
260-7.4-43.52941176471717.621.545711345.1037563CS

PSTX - Frequently Asked Questions (FAQ)

What is the current Poseida Therapeutics share price?
The current share price of Poseida Therapeutics is US$ 9,60
How many Poseida Therapeutics shares are in issue?
Poseida Therapeutics has 97.465.024 shares in issue
What is the market cap of Poseida Therapeutics?
The market capitalisation of Poseida Therapeutics is USD 931,77M
What is the 1 year trading range for Poseida Therapeutics share price?
Poseida Therapeutics has traded in the range of US$ 1,87 to US$ 9,67 during the past year
What is the PE ratio of Poseida Therapeutics?
The price to earnings ratio of Poseida Therapeutics is -7,59
What is the cash to sales ratio of Poseida Therapeutics?
The cash to sales ratio of Poseida Therapeutics is 14,48
What is the reporting currency for Poseida Therapeutics?
Poseida Therapeutics reports financial results in USD
What is the latest annual turnover for Poseida Therapeutics?
The latest annual turnover of Poseida Therapeutics is USD 64,7M
What is the latest annual profit for Poseida Therapeutics?
The latest annual profit of Poseida Therapeutics is USD -123,43M
What is the registered address of Poseida Therapeutics?
The registered address for Poseida Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Poseida Therapeutics website address?
The website address for Poseida Therapeutics is www.poseida.com
Which industry sector does Poseida Therapeutics operate in?
Poseida Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
HOTHHoth Therapeutics Inc
US$ 2,61
(218,45%)
371,18M
DATSDatChat Inc
US$ 5,44
(177,55%)
98,52M
SPISPI Energy Company Ltd
US$ 0,87
(102,33%)
101,41M
SVMHSRIVARU Holding Ltd
US$ 0,0851
(83,80%)
1,01B
CDTConduit Pharmaceuticals Inc
US$ 0,108101
(49,52%)
203,23M
SLRNACELYRIN Inc
US$ 2,18
(-37,54%)
9,56M
DHAIDIH Holdings US Inc
US$ 1,84
(-36,99%)
1,3M
AMSTAmesite Inc
US$ 2,67
(-34,07%)
773,82k
CISOCISO Global Inc
US$ 1,86
(-31,11%)
358,01k
BOXLBoxlight Corporation
US$ 1,1707
(-30,32%)
5,36M
XTIAXTI Aerospace Inc
US$ 0,1053
(19,66%)
2,2B
SVMHSRIVARU Holding Ltd
US$ 0,0851
(83,80%)
1,01B
CEROCERo Therapeutics Holdings Inc
US$ 0,0616
(45,63%)
823M
RIMEAlgorhythm Holdings Inc
US$ 0,2153
(48,69%)
629,34M
HOTHHoth Therapeutics Inc
US$ 2,61
(218,45%)
371,18M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
PSTX
Poseida Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten